Covid-19 roundup: Regeneron asks FDA: Which government agencies are tracking variants of concern?; Pfizer, AstraZeneca vaccines mostly hold strong against Delta variant
As the race to keep Covid-19 variants at bay continues, Regeneron is calling on the FDA to provide additional clarity on which government agencies are actually tracking and publishing lists on variants of concern like the Delta variant.
The New York-based biotech, which has made a name for itself during the pandemic for not only treating former President Trump with its antibody cocktail but also developing a cocktail that can withstand the changing nature of the coronavirus in the US. Meanwhile, its competitors from Eli Lilly were pulled from the market late last month as variants were able to penetrate the firm’s antibody drugs.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.